References
- Costanzo R, Montanino A, Di Maio M, Piccirillo MC, Sandomenico C, Giordano P, Daniele G, Franco R, Perrone F, Rocco G, Normanno N, Morabito A. Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives. Expert Rev Anticancer Ther 2013;13:1207–18.
- Sarkar S, Rajput S, Tripathi AK, Mandal M. Targeted therapy against EGFR and VEGFR using ZD6474 enhances the therapeutic potential of UV-B phototherapy in breast cancer cells. Mol Cancer 2013;12:122.
- Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J. Multi-institutional randomized phase I1 trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer: one IDEAL l Tria1. J Clin Oncol 2003;21:2237–46.
- Yang Z, Bagheri-Yarmand R, Wang RA, Adam L, Papadimitrakopoulou VV, Clayman GL, El-Naggar A, Lotan R, Barnes CJ, Hong WK, Kumar R. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells. Clin Cancer Res 2004;10: 658–67.
- Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer correlation with clinical response to gefitinib therapy. Science 2004; 304:1497–500.
- Taton TA, Mirkin CA and Letsinger RL. Scanometric DNA array detection with nanoparticle probes. Science 2000;289:1757–60.
- He C, Liu M, Zhou C, Zhang J, Ouyang M, Zhong N, Xu J. Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer. Int J Cancer 2009;125: 2393–9.
- Soh J, Toyooka S, Aoe K, Asano H, Ichihara S, Katayama H, Hiraki A, Kiura K, Aoe M, Sano Y, Sugi K, Shimizu N, Date H. Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer. Int J Cancer 2006;119:2353–8.
- Jin R, Wu G, Li Z, Mirkin CA, Schatz GC. What controls the melting properties of DNA-linked gold nanoparticle assemblies? J Am Chem Soc 2003;125: 1643–54.
- He Y, Zhang X, Zhang S, Kris MK, Man FC, Kawde AN, Liu G.Visual detection of single-base mismatches in DNA using hairpin oligonucleotide with double-target DNA binding sequences and gold nanoparticles. Biosens Bioelectron 2012;34:37–43.
- Lee JS, Stoeva SI, Mirkin CA. DNA-induced size-selective separation of mixtures of gold nanoaparticles. J Am Chem Soc 2006;128:8899–903.
- Pork SJ, Taton TA, Mirkin CA. Array-based electrical detection of DNA with nanoparticle probe. Science 2002;295:1503–6.
- Storhoff JJ, Lucas AD, Garimella V, Bao YP, Müller UR. Homogeneous detection of unamplified genomic DNA sequences based on colorimetric scatter of gold nanoparticle probes. Nat Biotechnol 2004;22: 883–7.
- Jiang B, Wang M, Chen Y, Xie J, Xiang Y. Highly sensitive electrochemical detection of cocaine on graphene/AuNP modified electrode via catalytic redox-recycling amplification. Biosens Bioelectron 2012;32:305–8.
- Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, Cortot AB, Chirieac L, Iacob RE, Padera R, Engen JR, Wong KK, Eck MJ, Gray NS, Jänne PA. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009;462:1070–4.
- Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C. Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 2012;4:127–36.